As we age, our bodies slow down the production of nicotinamide adenine dinucleotide (NAD+). Recent studies have revealed that low cellular levels of NAD+ cause ageing related disorders and chronic illnesses, such as diabetes, heart disease, Alzheimer’s and vision impairment.
Many experts believe that combating the decline of NAD+ levels may hold the key to reverse signs of ageing and chronic disease.
Nicotinamide Mononucleotide (NMN) is a NAD+ precursor, and has been shown to effectively increase cellular levels of NAD+.
Whilst human studies on NMN are limited, the information we do have has been overwhelming positive and proves to hold enormous promise for the potential of this molecule.
One recent study which involved administering NMN to a group of 20-month old mice – the equivalent of 70 in human years.
The study found that the mice that supplemented with NMN showed between a 56 and 80 percent greater exercise capacity, compared with untreated mice in the study.
Other studies have shown increased metabolism, reduced cardiovascular disease, increased energy, improved eye function and increased bone density from supplementing with the molecule.
NAD+ is essential for many of our bodies processes, and whilst NAD+ levels fall as we age, supplementing with NMN can increase NAD+ levels, thus combating many age related diseases.